384 related articles for article (PubMed ID: 22813834)
1. The impact of terminal complement blockade on the efficacy of induction with polyclonal rabbit antithymocyte globulin in living donor renal allografts.
Goh BK; Chedid MF; Gloor JM; Raghavaiah S; Stegall MD
Transpl Immunol; 2012 Oct; 27(2-3):95-100. PubMed ID: 22813834
[TBL] [Abstract][Full Text] [Related]
2. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation.
Pilch NA; Taber DJ; Moussa O; Thomas B; Denmark S; Meadows HB; McGillicuddy JW; Srinivas TR; Baliga PK; Chavin KD
Ann Surg; 2014 May; 259(5):888-93. PubMed ID: 24513787
[TBL] [Abstract][Full Text] [Related]
3. Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation.
Ruggenenti P; Codreanu I; Cravedi P; Perna A; Gotti E; Remuzzi G
Clin J Am Soc Nephrol; 2006 May; 1(3):546-54. PubMed ID: 17699258
[TBL] [Abstract][Full Text] [Related]
4. Low-dose RATG with or without basiliximab in renal transplantation: a matched-cohort observational study.
Gentile G; Somma C; Gennarini A; Mastroluca D; Rota G; Lacanna F; Locatelli B; Remuzzi G; Ruggenenti P
Am J Nephrol; 2015; 41(1):16-27. PubMed ID: 25612603
[TBL] [Abstract][Full Text] [Related]
5. Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation.
Sageshima J; Ciancio G; Guerra G; Gaynor JJ; Cova D; Zarak A; Chen L; Mattiazzi A; Kupin W; Roth D; Hanson L; Livingstone AS; Ruiz P; Burke GW
Transpl Immunol; 2011 Sep; 25(2-3):104-11. PubMed ID: 21784152
[TBL] [Abstract][Full Text] [Related]
6. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up.
Laftavi MR; Alnimri M; Weber-Shrikant E; Kohli R; Said M; Patel S; Pankewycz O
Transplant Proc; 2011 Mar; 43(2):458-61. PubMed ID: 21440733
[TBL] [Abstract][Full Text] [Related]
7. 5-year results of a prospective, randomized, single-center study of alemtuzumab compared with rabbit antithymocyte globulin induction in simultaneous kidney-pancreas transplantation.
Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Farney AC
Transplant Proc; 2014; 46(6):1928-31. PubMed ID: 25131073
[TBL] [Abstract][Full Text] [Related]
8. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection.
Deeks ED; Keating GM
Drugs; 2009 Jul; 69(11):1483-512. PubMed ID: 19634926
[TBL] [Abstract][Full Text] [Related]
9. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
[TBL] [Abstract][Full Text] [Related]
10. Low Immunologic Risk Living Related Renal Transplant Using Very Low-Dose Antithymocyte Globulin as Induction Therapy: A Single Tertiary Hospital Experience.
Jalalonmuhali M; Ng KP; Ong CS; Lee YW; Wan Md Adnan WAH; Lim SK
Transplant Proc; 2020; 52(6):1709-1714. PubMed ID: 32448669
[TBL] [Abstract][Full Text] [Related]
11. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation.
Flaman F; Zieroth S; Rao V; Ross H; Delgado DH
J Heart Lung Transplant; 2006 Nov; 25(11):1358-62. PubMed ID: 17097501
[TBL] [Abstract][Full Text] [Related]
12. The impact of induction therapy on the homeostasis and function of regulatory T cells in kidney transplant patients.
Bouvy AP; Klepper M; Kho MM; Boer K; Betjes MG; Weimar W; Baan CC
Nephrol Dial Transplant; 2014 Aug; 29(8):1587-97. PubMed ID: 24771499
[TBL] [Abstract][Full Text] [Related]
13. Comparison of clinical outcome of low-dose and high-dose rabbit antithymocyte globulin induction therapy in renal transplantation: a single-center experience.
Yang JW; Wang JN; Men TY; Zhang XM; Li XD; Shen B; Li GY; Chen DD
Ann Transplant; 2014 Jun; 19():277-82. PubMed ID: 24906405
[TBL] [Abstract][Full Text] [Related]
14. Basiliximab versus rabbit antithymocyte globulin as induction therapy for living-related renal transplantation: a single-center experience.
Huang HF; Zhou JY; Xie WQ; Wu JY; Deng H; Chen JH
Int Urol Nephrol; 2016 Aug; 48(8):1363-1370. PubMed ID: 27170340
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of extended-duration inpatient-to-outpatient rabbit antithymocyte globulin induction in de novo kidney transplant recipients: 6-month outcomes.
Trofe-Clark J; Reese PP; Patel HJ; Jakobowski D; Goral S; Doll SL; Abt PL; Bloom RD
Transplantation; 2012 Sep; 94(5):506-12. PubMed ID: 22895613
[TBL] [Abstract][Full Text] [Related]
16. Regulatory T cells in kidney transplant recipients: the effect of induction immunosuppression therapy.
Krystufkova E; Sekerkova A; Striz I; Brabcova I; Girmanova E; Viklicky O
Nephrol Dial Transplant; 2012 Jun; 27(6):2576-82. PubMed ID: 22167587
[TBL] [Abstract][Full Text] [Related]
17. Low-dose rabbit antithymocyte globulin induction therapy results in prolonged selective lymphocyte depletion irrespective of maintenance immunosuppression.
Pankewycz O; Leca N; Kohli R; Wallace PK; Said M; Feng L; Alnimri M; Patel S; Laftavi MR
Transplant Proc; 2011 Mar; 43(2):462-5. PubMed ID: 21440734
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
[TBL] [Abstract][Full Text] [Related]
19. Rabbit antithymocyte globulin induction therapy in adult renal transplantation.
Hardinger KL
Pharmacotherapy; 2006 Dec; 26(12):1771-83. PubMed ID: 17125438
[TBL] [Abstract][Full Text] [Related]
20. In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development.
Todeschini M; Cortinovis M; Perico N; Poli F; Innocente A; Cavinato RA; Gotti E; Ruggenenti P; Gaspari F; Noris M; Remuzzi G; Casiraghi F
J Immunol; 2013 Sep; 191(5):2818-28. PubMed ID: 23913968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
